The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: JLL Partners

Monday Biotech Deal Review: December 7, 2009

1 Comment Posted by Jeremy Grushcow on December 7, 2009

This was a fairly busy week for Canadian biotech deals, including a new brain-y collaboration for MaRS; peace at Patheon; some overallotment and some underallotment; some diversification by Canadian pharma (even if not on quite the scale of Pfizer’s deal with Protalix); and some trans-Atlantic acquisitiveness of a Canadian company’s own devicing [sic., sorry]. Don’t [...]

Jeremy Grushcow, Monday Deal Review Agrisoma, Amorfix, Aptilon, Baycrest, Cogniciti, Dow AgroSciences, IMRIS, Intelliject, Jenex Corporation, JLL Partners, MaRS, Oncolytics, Patheon, Prism Medical, sanofi-aventis Canada, Sentinelle Medical, Siemens Healthcare, SQI Diagnostics, Ultrasonix Medical

Monday Biotech Deal Review: September 28, 2009

1 Comment Posted by Jeremy Grushcow on September 28, 2009

Lots of deal news this week, including the Canadian action noted at the time: the iCo-CPDD deal and ethica’s in-license transaction. Plus there was plenty of international excitement today (repentance notwithstanding) with Abbott’s $6.6 billion Solvay play and J&J’s new 18% stake in Crucell. Keep reading for a securities-palooza and plenty more

Jeremy Grushcow, Monday Deal Review Aegera Therapeutics, Agrium, ALDA Pharmaceuticals Corp., CF Industries, Investissement Quebec, JLL Partners, Lonza, Oncolytics, Patheon, Primera Bioscience, SickKids, Sonomax Hearing Healthcare, SXC Health Solutions

Update Released by Patheon’s Special Commmittee

Leave a Comment Posted by Jeremy Grushcow on September 17, 2009

Patheon’s Special Committee provided an update today: “The Special Committee of Independent Directors of Patheon Inc. … today provided an update on its discussions with Lonza Group AG … regarding Lonza’s previously announced non-binding proposal to acquire all of the outstanding restricted voting shares of the Company at a price of US$3.55 per share. The [...]

Jeremy Grushcow, News JLL Partners, Lonza, Patheon, Special Committee, takeover bid

Patheon Special Committee Responds to JLL Statements

Leave a Comment Posted by Jeremy Grushcow on August 28, 2009

Patheon’s special committee issued a press release today in which it: “commented … on the recent expiry of the unsuccessful bid by JLL … and recent statements by JLL regarding the previously announced proposal by Lonza … to acquire all of the outstanding Shares at a price of US$3.55 per share.”

Jeremy Grushcow, News JLL Partners, Lonza, Patheon

Monday Deal Review: August 24, 2009

1 Comment Posted by Jeremy Grushcow on August 24, 2009

This week saw a few headline deals that we covered at the time, including the Vasogen-Cervus-IntelliPharmaCeutics deal, the move by Takeda Canada to take back ACTOS rights from Lilly, and the Lonza offer for Patheon, but other than that it seems like it was a quiet week everywhere. Still, check out some good stuff

Jeremy Grushcow, Monday Deal Review Ajanta Pharma, Angiotech, Cervus, Colabor Income Fund, ConjuChem, Eli Lilly, IntelliPharmaCeutics, JLL Partners, Lonza, Medicago, MedMira, Patheon, Rex Medical, Takeda Canada, Vasogen

Lonza Offers $460 Million for Patheon, JLL Rejects

Leave a Comment Posted by Jeremy Grushcow on August 21, 2009

JLL Partners’ long-standing bid for Patheon took a turn this morning as Lonza Group AG announced their own bid. Here’s Lonza’s press release. Here’s JLL’s response, rejecting the offer. Stay tuned…

Jeremy Grushcow, News JLL Partners, Lonza, Patheon

Monday Deal Review: August 17, 2009

3 Comments Posted by Jeremy Grushcow on August 17, 2009

In addition to the highlights already noted — Enobia’s $50 million r0und, and the LOM – BioQuest joint venture — there was plenty of other Canadian deal activity this week. Check it out

Jeremy Grushcow, Monday Deal Review BioQuest, BioSyntech, Clinical Data Inc., Colabor Income Fund, CombinatoRx, ConjuChem, Enobia, GeneNews, IMBiotechnologies, Jennerex, JLL Partners, LAB Research Inc., LOM, Medicure Inc., MedMira, Neuromed, Oncothyreon, Pacgen Biopharmaceuticals, Paladin Labs, Patheon, Prism Medical, Pyng Medical, Rosetta Genomics, Warex Medical Laboratories, Xphase Pharmaceuticals

Globe and Mail Story on Patheon-JLL Battle

1 Comment Posted by Jeremy Grushcow on July 30, 2009

Boyd Erman at the Globe and Mail wrote about JLL’s long battle for Patheon in this morning’s paper, following yesterday’s dueling press releases (which I tweeted about @crossborderbio, also appearing to your right on this blog). Particularly if you’re new to this saga, I encourage you to read the whole article; but for those who [...]

Jeremy Grushcow, News Boyd Erman, Globe and Mail, JLL Partners, Maher Yaghi, MOVA, Patheon

Monday Deal Review: July 20, 2009

Leave a Comment Posted by Jeremy Grushcow on July 20, 2009

This week’s deal review has some more info about Ambrilia’s deal with Kotinos that I tweeted about at the time (my Twitter stream shows up in the sidebar on the right here), as well as an update on JLL-Patheon and a raft of securities deals, including an issuer bid

Jeremy Grushcow, Monday Deal Review ALERT B&C, Ambrilia Biopharma, Bradmer Pharmaceuticals, iCo Therapeutics, JLL Partners, Kotinos Pharmaceuticals, MedBioGene, Patheon, PharmaGap, SEP Capital

Monday Deal Review: June 22, 2009

5 Comments Posted by Jeremy Grushcow on June 22, 2009

A whole gaggle of securities deals, a cluster of licenses and a flock of M&A all migrate back to Canada for summer in this week’s Monday Deal Review. Plus, a deal that may improve the medical isotope shortage.

Jeremy Grushcow, Monday Deal Review Aeterna Zentaris, Akela Pharma, ALERT B&C, Amorfix, Covidien, Isotechnika, JLL Partners, Karpov Institute of Physical Chemistry, Mallinckrodt, MDS Nordion, MedMira, Neuromed, Nuvo Research, Nventa Biopharmaceuticals, Otto Bock, Paladin Labs, Patheon, PharmaGap, SemBioSys Genetics Inc., Teikoku Seiyaku, Victhom Human Bionics

Monday Deal Review: June 8, 2009

4 Comments Posted by Jeremy Grushcow on June 9, 2009

Well, it’s a day late, but no dollars short. Here is an action-packed Deal Review. Read on for some debt settlement, some creditor un-settlment (a BIA filing), and all kinds of M&A related rejigging…

Jeremy Grushcow, Monday Deal Review Atwell Capital, AVENTIX Animal Health, Baylis Medical Company, debt settlement, Eklin Medical Systems, Fralex Therapeutics, JLL Partners, LMS Medical Systems, MDS Inc., MDS Pharma Services, MedMira, Patheon, Theratechnologies, Vineland Research and Innovation Centre

Patheon and JLL Head (Back) to Court

Leave a Comment Posted by Jeremy Grushcow on May 26, 2009

If you’ve been following the Canadian takeover saga that is JLL Partners’ bid for Patheon, you’ll be not at all surprised to learn that litigation is now pending. Read all the gory details from today’s announcement by Patheon’s Special Committee of Independent Directors

Jeremy Grushcow, News JLL Partners, Patheon, takeover bid

Monday Deal Review: May 25, 2009

4 Comments Posted by Jeremy Grushcow on May 25, 2009

This week’s deal review has a couple of new placements, a couple of new plants, a very interesting claim asserted in Boston, and many, many updates on deals we have previously covered. Check out the full review

Jeremy Grushcow, Monday Deal Review Akela Pharma, Cardiome Pharma, Enerkem, GreenField, Haemacure, JLL Partners, Massachusetts General Hospital, MEEI, Merck, Microbix Biosystems, Mississauga, Nventa Biopharmaceuticals, Patheon, QLT, Response Biomedical

Monday Deal Review: May 11, 2009

5 Comments Posted by Jeremy Grushcow on May 11, 2009

Check out the latest Patheon-JLL developments, a licensing deal that looks like a subcontracting arrangement, a plan of arrangement M&A that looks like a license, and the rest of the Canadian deal info from this past week

Jeremy Grushcow, Monday Deal Review Angiotech, AVAC, Cangene, Haemacure, Isotechnika, JLL Partners, Maxygen, MedMira, Paladin Labs, Patheon, Response Biomedical, Roche, SemBioSys Genetics Inc., voclosporin

Monday Deal Review: May 4, 2009

3 Comments Posted by Jeremy Grushcow on May 4, 2009

Canadian deal and company news this week: Big drama at Patheon’s AGM, a public offering (!), some collaboration news and a completed private placement.

Jeremy Grushcow, Monday Deal Review Aeterna Zentaris, Amorfix, annual meeting, DiagnoCure, JLL Partners, Listing requirements, Oncolytics, Otto Bock, Patheon, private placement, prospectus, proxy fight, public offering, Victhom Human Bionics

Monday Deal Review: April 27, 2009

2 Comments Posted by Jeremy Grushcow on April 27, 2009

Biotech deal activity in Canada was back on the upswing a bit this week, with some private placements, issuer bids, and an equity line of credit…

Jeremy Grushcow, Monday Deal Review Amorfix, BioMosaics, equity line of credit, JLL Partners, MedMira, Neovasc, OICR, Patheon, private placement, Sunnybrook Research Institute

Monday Deal Review: April 20, 2009

1 Comment Posted by Jeremy Grushcow on April 20, 2009

A relatively quiet week for the deal review this week…

Jeremy Grushcow, Monday Deal Review Advitech, Apotex, Cangene, Department of Defense, Fralex Therapeutics, JLL Partners, NEX board, NGN Capital, Patheon, Resverlogix, TSX-V

Monday Deal Review: April 13, 2009

3 Comments Posted by Jeremy Grushcow on April 13, 2009

M&A, scads of securities, and a real, live IPO in the Canadian deal news this week.

Jeremy Grushcow, Monday Deal Review Applied Biosystems, Aptilon, Biotanika Health Group, Canaccord, CRH Medical, GenoLogics, IPO, JLL Partners, Kiadis, LMS Medical Systems, McKesson, Medifocus, Nuvo Research, Oncolytics, Orcrist, Patheon, PreMD, PREZISTA, Welichem

Wednesday Brain Dump: Deal-O-Rama Edition

1 Comment Posted by Jeremy Grushcow on April 1, 2009

There’s still plenty of deal activity in the pharma and biotech sector this week, even outside Canada, so here’s a roundup of what’s done, what’s pending and what’s in the rumor mill:

Jeremy Grushcow, Wednesday Brain Dump Abbott, Aspen Pharmacare, Aveo, Bayer HealthCare, Biogen, Campath, Fludara, Genzyme, GlaxoSmithKline, HGS, Human Genome Sciences, Infosys, JLL Partners, leukemia, Leukine, Lilly, Morphotek, Nycomed, Patheon, Pfizer, PharmaNet, Solvay, TriLipix, Zydus

Monday Deal Review: March 30, 2009

3 Comments Posted by Jeremy Grushcow on March 30, 2009

Canadian deal and company info from this week

Jeremy Grushcow, Monday Deal Review Arabian Medical Marketing Co., covertible loan, EMD Serono, Exalgo, Foundation for Innovative New Diagnostics, InNexus Biotechnology, Isotechnika, JLL Partners, Lilly, Lux Biosciences, Medicago, Merck KGaA, Neuromed, nimotuzumab, Oncolytics, Ottawa Health Research Institute, Palex Medical, Patheon, PharmaGap, Protox Therapeutics, Response Biomedical, takeover bid, tesamorelin, Theratechnologies, Transition Therapeutics, TT-223, type 2 diabetes, voclosporin, warrants, YM Biosciences

Monday Deal Review: March 16, 2009

3 Comments Posted by Jeremy Grushcow on March 16, 2009

M&A: We already noted the JLL bid for Patheon this week, and the Patheon Special Committee’s response. It turns out that JLL has been a busy enterprise lately, extending the expiration on a bid for PharmaNet Development Group, Inc. (Nasdaq: PDGI). Partnering: MedMira Inc., (TSX-V:MIR, NASDAQ: MMIRF), which has been active on the securities front with a [...]

Jeremy Grushcow, Monday Deal Review Advitech, AgeChem, Akela Pharma, Caisse de Depot, Cytognomix, delisting review, Helix BioPharma, HIV Test, JLL Partners, LAB Research Inc., litigation settlement, LMS Medical Systems, MedMira, Michael Sabia, Ontario Genomics Institute, Patheon, PharmaNet, Pre-commercialization Business Development Fund, private placement, Resverlogix, Spectral Diagnostics, Toray Industries, Vitest

Patheon Special Committee Bites its Thumb at JLL’s Bid. Clubs, Bills and Partisans to Follow!

2 Comments Posted by Jeremy Grushcow on March 12, 2009

Following JLL’s commencement of its bid for Patheon yesterday, Patheon’s Special Committee released its response this morning advising shareholders that JLL’s offer is “substantially undervalued, opportunistic and structurally coercive.” Patheon shares closed up slightly at $2.55 (up 0.79% from $2.53 yesterday), approximately matching the gains made by the Canadian dollar (up 0.55% today). JLL’s bid [...]

Jeremy Grushcow, News JLL Partners, M&A, Patheon, takeover bid

Canadian M&A Update: JLL Commences Patheon Bid at USD$2.00 per share

4 Comments Posted by Jeremy Grushcow on March 11, 2009

JLL Partners’ bid for Patheon Inc. (TSX: PTI), which has been brewing since December at the same USD$2.00 price, turned into a takeover bid today, with JLL announcing the lockup of shareholders holding 12,581,766 (about 13.8% by my calculation) of the subject shares. As we noted in the Monday Deal Review February 23, Patheon has [...]

Jeremy Grushcow, News anti-takeover, JLL Partners, M&A, Patheon, poison pills, takeover bid

Monday Deal Review: February 23, 2009

1 Comment Posted by Jeremy Grushcow on February 23, 2009

Canadian deals and company info this week

Jeremy Grushcow, Monday Deal Review 505(b)(2), Amorfix, Bioniche, BioSyntech, Cipher Pharmaceuticals, convertible debentures, Defyrus, iCo Therapeutics, IMRIS, JLL Partners, Medworxx, Patheon, PharmaGap, Ploughshare Innovation, PMH, Sentinelle Medical, Siemens Healthcare, takeover bid, UHN, UK Defence Science Technology Laboratory, Ultram ER

RSS feed

The views expressed here are solely the authors’ and should not be attributed to any of their firms or clients. The material and information provided on this website are for general information only and should not be relied on as legal or business advice or as a legal opinion. The authors make no claims, promises or guarantees about the accuracy, completeness, currency, or adequacy of any information linked or referred to or contained on this blog. No person should act or refrain from acting in reliance on any information found on this blog without first obtaining appropriate professional advice from a consultant or from a lawyer duly licensed to practise law in the relevant province, state, territory or country. These materials do not create a solicitor-client relationship between you and any author. Please note that the authors will not provide free legal, financial or other advice. Please don’t send us any confidential information or questions by email or otherwise because any information sent to us cannot be considered to be privileged or confidential. Note that by accessing, commenting on or linking to the blog, you (like us) are subject to the WordPress Terms of Service. Most images are from Wikimedia Commons or from governments, others link back to commercial sources. If you want us to remove an image, just let us know.